548 related articles for article (PubMed ID: 18322366)
1. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness.
Hornykiewicz O
Neurodegener Dis; 2008; 5(3-4):114-7. PubMed ID: 18322366
[TBL] [Abstract][Full Text] [Related]
2. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent.
Hornykiewicz O
Amino Acids; 2002; 23(1-3):65-70. PubMed ID: 12373520
[TBL] [Abstract][Full Text] [Related]
3. [Short history of L-Dopa].
García Ruiz PJ; Meseguer E
Neurologia; 2002 Apr; 17(4):214-7. PubMed ID: 11940409
[TBL] [Abstract][Full Text] [Related]
4. [Drug therapy in Parkinson's disease].
van Hilten JJ; Roos RA
Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
[TBL] [Abstract][Full Text] [Related]
5. Transplantation of autologous sympathetic neurons as a potential strategy to restore metabolic functions of the damaged nigrostriatal dopamine nerve terminals in Parkinson's disease.
Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
Brain Res Rev; 2006 Sep; 52(2):244-56. PubMed ID: 16644019
[TBL] [Abstract][Full Text] [Related]
6. [Medicinal treatment of idiopathic Parkinson's disease].
Klockgether T
Nervenarzt; 2003 Mar; 74 Suppl 1():S12-21. PubMed ID: 12624679
[TBL] [Abstract][Full Text] [Related]
7. Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.
St-Hilaire M; Bourhis E; Lévesque D; Rouillard C
Eur J Neurosci; 2006 Aug; 24(3):795-805. PubMed ID: 16930409
[TBL] [Abstract][Full Text] [Related]
8. The history of dopamine and levodopa in the treatment of Parkinson's disease.
Fahn S
Mov Disord; 2008; 23 Suppl 3():S497-508. PubMed ID: 18781671
[TBL] [Abstract][Full Text] [Related]
9. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
[TBL] [Abstract][Full Text] [Related]
10. [Dopamine agonists in the therapy of parkinson syndrome].
Kapfhammer HP; Rüther E
Nervenarzt; 1985 Feb; 56(2):69-81. PubMed ID: 3982566
[No Abstract] [Full Text] [Related]
11. Interactions of exogenous L-dopa with nigrostriatal dopaminergic neurons in Parkinson's disease.
Melamed E
Adv Neurol; 1990; 53():61-6. PubMed ID: 2173376
[No Abstract] [Full Text] [Related]
12. Partial dopamine loss enhances activated caspase-3 activity: differential outcomes in striatal projection systems.
Ariano MA; Grissell AE; Littlejohn FC; Buchanan TM; Elsworth JD; Collier TJ; Steece-Collier K
J Neurosci Res; 2005 Nov; 82(3):387-96. PubMed ID: 16180225
[TBL] [Abstract][Full Text] [Related]
13. Clinical features, diagnosis, and imaging of parkinsonian syndromes.
Poewe W
Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):333-8. PubMed ID: 8507902
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
[TBL] [Abstract][Full Text] [Related]
15. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
Olanow CW
Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
[TBL] [Abstract][Full Text] [Related]
16. Role of the nigrostriatal dopaminergic neurons in mediating the effect of exogenous L-dopa in Parkinson's disease.
Melamed E
Mt Sinai J Med; 1988 Jan; 55(1):35-42. PubMed ID: 3279303
[No Abstract] [Full Text] [Related]
17. Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA.
Darmopil S; Muñetón-Gómez VC; de Ceballos ML; Bernson M; Moratalla R
Eur J Neurosci; 2008 Feb; 27(3):580-92. PubMed ID: 18279311
[TBL] [Abstract][Full Text] [Related]
18. L-dopa therapy for Parkinson's disease: past, present, and future.
Nagatsua T; Sawadab M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S3-8. PubMed ID: 19131039
[TBL] [Abstract][Full Text] [Related]
19. Does treatment with dopamine agonists affect utilization of exogenous levodopa in the parkinsonian striatum?
Melamed E
J Neural Transm Suppl; 1995; 45():57-60. PubMed ID: 8748609
[TBL] [Abstract][Full Text] [Related]
20. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
Lees AJ; Tolosa E; Olanow CW
Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
